Robert J Petrella1, Luc Sauriol2. 1. Department of Family Medicine and Cardiology, The University of Western Ontario Lawson Health Research Institute, 801 Commissioners Rd East, Suite B-3002, London, Ontario, N6C 5J1, Canada. 2. Manager, Health Economic and Health Outcomes, Sanofi Aventis Canada,2150 St-Elzéar Ouest, Laval, Qc, H7L 4A8.
Abstract
Background: Information about current practice in primary care-based management of atrial fibrillation (AF) can help to improve care quality. Purpose: To assess the epidemiology of AF and current patterns of treatment in order to identify therapeutic trends and aspects of current practice that may allow for care-gap identification. Methods: We scrutinized the anonymized records of the South Western Ontario database (SWO) collected between July 2002 and October 2008 for information about the characteristics and management of AF patients. Results: From a population of ~168,000 patients we identified 4922 patients with a diagnosis of AF (2.9%). The recorded prevalence of AF increased with age, from <2% at age <60 years to 6% in the age range 71-75 years and 10% at age ≥81 years. AF patients were characterized by an unfavourable cardiovascular risk profile including widespread hypertension (54% of all cases), coronary artery disease (37%) and heart failure (21%), many cases of which were advanced (New York Heart Association class III or IV). Diabetes (22%) and dyslipidaemia (31%) were also widely prevalent. The most frequently prescribed anti-arrhythmic drugs (AADs) were sotolol (n=798), amiodarone (n=712) and propafenone (n=451). Recorded use of flecainide was relatively low (n=175). Rate control-agents were being prescribed for 1838 patients, beta-blockers for 1311 patients and calcium channel blockers (CCBs) for 784 patients. Use of anticoagulants was higher among patients assigned to AADs than among those assigned to rate-control drugs (>25% vs. ~10%). Overall prescription rates for other concomitant medications were >50% for ACE inhibitors/ARBs, 30-35% for statins and beta-blockers, and 27-29% for diuretics, digoxin and CCBs. Conclusions: These Canadian patients with AF were relatively elderly and had multiple concomitant cardiovascular conditions and medications.
Background: Information about current practice in primary care-based management of atrial fibrillation (AF) can help to improve care quality. Purpose: To assess the epidemiology of AF and current patterns of treatment in order to identify therapeutic trends and aspects of current practice that may allow for care-gap identification. Methods: We scrutinized the anonymized records of the South Western Ontario database (SWO) collected between July 2002 and October 2008 for information about the characteristics and management of AFpatients. Results: From a population of ~168,000 patients we identified 4922 patients with a diagnosis of AF (2.9%). The recorded prevalence of AF increased with age, from <2% at age <60 years to 6% in the age range 71-75 years and 10% at age ≥81 years. AFpatients were characterized by an unfavourable cardiovascular risk profile including widespread hypertension (54% of all cases), coronary artery disease (37%) and heart failure (21%), many cases of which were advanced (New York Heart Association class III or IV). Diabetes (22%) and dyslipidaemia (31%) were also widely prevalent. The most frequently prescribed anti-arrhythmic drugs (AADs) were sotolol (n=798), amiodarone (n=712) and propafenone (n=451). Recorded use of flecainide was relatively low (n=175). Rate control-agents were being prescribed for 1838 patients, beta-blockers for 1311 patients and calcium channel blockers (CCBs) for 784 patients. Use of anticoagulants was higher among patients assigned to AADs than among those assigned to rate-control drugs (>25% vs. ~10%). Overall prescription rates for other concomitant medications were >50% for ACE inhibitors/ARBs, 30-35% for statins and beta-blockers, and 27-29% for diuretics, digoxin and CCBs. Conclusions: These Canadian patients with AF were relatively elderly and had multiple concomitant cardiovascular conditions and medications.
Authors: L Samuel Wann; Anne B Curtis; Craig T January; Kenneth A Ellenbogen; James E Lowe; N A Mark Estes; Richard L Page; Michael D Ezekowitz; David J Slotwiner; Warren M Jackman; William G Stevenson; Cynthia M Tracy; Valentin Fuster; Lars E Rydén; David S Cannom; Jean-Yves Le Heuzey; Harry J Crijns; James E Lowe; Anne B Curtis; S Bertil Olsson; Kenneth A Ellenbogen; Eric N Prystowsky; Jonathan L Halperin; Juan Luis Tamargo; G Neal Kay; L Samuel Wann; Alice K Jacobs; Jeffrey L Anderson; Nancy Albert; Judith S Hochman; Christopher E Buller; Frederick G Kushner; Mark A Creager; Erik Magnus Ohman; Steven M Ettinger; William G Stevenson; Robert A Guyton; Lynn G Tarkington; Jonathan L Halperin; Clyde W Yancy Journal: Circulation Date: 2010-12-20 Impact factor: 29.690
Authors: Kamakshi Lakshminarayan; Craig A Solid; Allan J Collins; David C Anderson; Charles A Herzog Journal: Stroke Date: 2006-06-29 Impact factor: 7.914
Authors: Jason G Andrade; Stuart J Connolly; Paul Dorian; Martin Green; Karin H Humphries; George J Klein; Robert Sheldon; Mario Talajic; Charles R Kerr Journal: Heart Rhythm Date: 2010-04-27 Impact factor: 6.343
Authors: Nancy M Allen LaPointe; Laura Governale; Jerry Watkins; Jyotsna Mulgund; Kevin J Anstrom Journal: Am Heart J Date: 2007-08-20 Impact factor: 4.749